✓ Every entry linked to its official government source

Clinical-trial readouts & FDA AdComm meetings — every entry source-anchored.

Upcoming clinical-trial readout windows (from ClinicalTrials.gov) and FDA Advisory Committee (AdComm) meetings (from the Federal Register), each linked to its official record and clearly labelled confirmed (a scheduled FDA meeting or completed event) or estimated (the sponsor's projected trial-completion date). Public scheduling data, not investment advice.

See the calendar → Get the feed / API

What "source-anchored" means here

Every row is read directly from an official government field and links straight back to it, stamped with the date we last checked. We do not dress up an estimate as a fixed date: trial-readout rows carry the sponsor's estimated primary-completion date (which can slip), while FDA AdComm meetings carry a confirmed, scheduled date from the Federal Register Notice of Meeting. Each row says which it is, and you can audit it in one click.

602

upcoming source-anchored catalysts

600

trial primary-completion / readout dates EST

75

FDA AdComm meetings CONFIRMED

286

mapped to a public ticker

Most upcoming entries are clinical-trial readout windows carrying the sponsor's estimated primary-completion date (it can slip). FDA AdComm meetings carry a confirmed scheduled date. Every row is labelled and linked to its official source.

Soonest upcoming catalysts

Source-checked 2026-06-22 · refreshed daily · full calendar →

Date	Event	Company	Drug	Official source & verification
2026-06-22 today ESTIMATED	READOUT Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) Wit Phase 2 · Waldenstrom Macroglobulinemia, Multiple Myeloma	CLRB Cellectar Biosciences, Inc.	Iopofosine I 131 single dose, Iopofosine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT Efficacy and Safety of Odevixibat in Children With Biliary Atresia Who Have Unde Phase 3 · Biliary Atresia	Albireo, an Ipsen Company	Odevixibat	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Rollover Study to Provide Continued Treatment for Participants Previously Enro Phase 2 · Myelofibrosis, Postlung Transplant (Bronchiolitis Obliterans)	INCY INCYTE CORP	itacitinib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab i Phase 3 · Atopic Dermatitis	AMGN AMGEN INC	Rocatinlimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-22 today ESTIMATED	READOUT A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectivene Phase 1/2 · Neoplasms, Colorectal, Solid Tumor	GlaxoSmithKline	GSK4418959, PD-1 inhibitor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-23 in 1d ESTIMATED	READOUT Safety Study in Subjects ≥ 12 Years of Age With Hereditary Angioedema Switching Phase 4 · Hereditary Angioedema	CSL Behring	Garadacimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study of Nipocalimab in Children Aged 2 to Less Than 18 Years With Generalized Phase 2/3 · Myasthenia Gravis	Janssen Research & Development, LL	Nipocalimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Phase 3 · Primary Biliary Cholangitis	Ipsen	Elafibranor	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-26 in 4d ESTIMATED	READOUT A Study to Explore the Efficacy of JNJ-89495120 in the Treatment of Major Depres Phase 2 · Depressive Disorder, Major	Janssen Research & Development, LL	JNJ-89495120	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) Phase 2 · NASH - Nonalcoholic Steatohepatitis	Hanmi Pharmaceutical Company Limit	HM15211	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWA Phase 1/2 · Duchenne Muscular Dystrophy	WVE Wave Life Sciences Ltd.	WVE-N531	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-27 in 5d ESTIMATED	READOUT A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cance Phase 2 · Cancer Harboring BRAF Alterations, HGG	Fore Biotherapeutics	Plixorafenib	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-29 in 7d ESTIMATED	READOUT Study of Olaparib (MK-7339) in Combination With Pembrolizumab (MK-3475) in the T Phase 2 · Solid Tumors	Merck Sharp & Dohme LLC	Olaparib, Pembrolizumab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-29 in 7d ESTIMATED	READOUT A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Su Phase 3 · Dermatitis Atopic	SNY Sanofi	Amlitelimab	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease Phase 2 · Stargardt Disease, Stargardt Macular Degeneration	Alkeus Pharmaceuticals, Inc.	ALK-001	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Open Label Extension to Assess the Long-Term Safety and Tolerability of ZYN002 i Phase 2/3 · Fragile X Syndrome	Zynerba Pharmaceuticals, Inc.	ZYN002 - Cannabidiol Transdermal Gel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleo Phase 2 · Thymidine Kinase 2 Deficiency	UCB BIOSCIENCES, Inc.	doxecitine and doxribtimine	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of NanO2™ Combined With Radiation and Temozolomide in Patients With Newl Phase 2 · Glioblastoma Multiforme	NuvOx LLC	NanO2TM	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/ Phase 1/2 · Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies	Beijing InnoCare Pharma Tech Co.,	Orelabrutinib (ICP-022)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Assessing the Impact of Lipoprotein (a) Lowering With Pelacarsen (TQJ230) on Maj Phase 3 · Cardiovascular Disease and Lipoprotein(a)	NVS NOVARTIS AG	TQJ230	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD- Phase 1/2 · Non Small Cell Lung Cancer, Advanced Solid Tumor	OncoC4, Inc.	ONC-392, Pembrolizumab, Docetaxel	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Phase 1/2 · B-cell Acute Lymphoblastic Leukemia	CLLS Cellectis S.A.	UCART22, CLLS52	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT Extension Study of P1101 After Completion of Phase 2 Study in PV Patients or Pha Phase 3 · Polycythemia Vera (PV)	PharmaEssentia Japan K.K.	P1101 (Ropeginterferon alfa-2b)	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Phase 3 · Relapsed or Refractory Follicular Lymphoma	Hoffmann-La Roche	Mosunetuzumab, Lenalidomide, Rituximab,	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change
2026-06-30 in 8d ESTIMATED	READOUT LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incom Phase 1/2 · Superficial Bladder Cancer, Non-muscle Invasive Bladder Cancer With Carcinoma in Situ	ENGN enGene Therapeutics Inc.	EG-70 (phase 1), EG-70 (phase 2) Master	ClinicalTrials.gov ↗ ✓ Source-checked 2026-06-22 Sponsor-projected date — can change